|
|
|
 |
|
|
|
| These guidelines are limited to non-Japanese ophthalmologists living outside of Japan who would like to submit abstracts as "international members". |
|
| Please send the entry form and your abstract to the Abstract Submission Office via e-mail after reading the following guidelines. |
|
Abstract Submission Deadline |
|
March 3 (Wed.) – 12:00 P.M, May 12 (Wed.) |
|
(Japan Standard Time, UTC+9) |
|
|
|
|
| |
|
|
Applicants' Qualification |
|
|
|
|
| |
| The first author (presenter) of a general presentation should be an international member of the Japanese Ophthalmological Society. Non-members at the time of application are eligible to apply and will be granted international membership after acceptance of abstract, endorsement from the presidents and approval by the Board. For further information on international membership, please see here. |
|
| |
|
| |
|
|
Application for General Presentation |
|
|
|
|
| |
| Note)
More than one application from the same author as the first presenter should not be accepted. None of the abstracts may be accepted when more than one application from the same first author is suspected. |
|
(1) |
|
|
| |
In the entry form, you will be asked the followings.
Please submit the form with your abstract to Abstract Submission office (ringan2021-abs@congre.co.jp). |
| |
|
| |
• |
Presentation Style (preference)* |
|
| |
(A) |
Free Paper: Oral Presentation (on site) |
|
| |
|
--- Computer-based presentation (Power Point) only (film slides or videotapes are not allowed) |
|
| |
(B) |
Free Paper: e-Poster Presentation (Web site only, no presentation on site) |
|
| |
|
--- Power Point presentation with audio (adding your speech to the presentation file) |
|
| |
| * |
Please note that the final decision of your presentation style will be made by the congress committee. Your choice could be changed to the other presentation style. |
|
| |
|
|
• |
Category (Regarding your abstract theme) |
|
| |
| 01 |
Cornea, Conjunctiva |
02 |
Lens, Cataract |
| 03 |
Glaucoma |
04 |
Retina, Vitreous body |
| 05 |
Ocular Inflammation, Infection, Uvea |
06 |
Strabismus, Amblyopia, Pediatric Ophthalmology, Neuro-Ophthalmology |
| 07 |
Refraction, Visual Function |
08 |
Tumor, Orbit, Eyelid, Lacrimal Functional Unit, Pathology, Pharmacology |
| 09 |
Low Vision, Color Vision, Electrophysiology |
10 |
Medical Services, Medical Politics, Others |
|
| |
|
|
| • |
Approval of the ethics committee |
| |
--- Select whether you have obtained an approval of the ethics committee, e.g. IRB, or if it is not applicable. This does not need to be stated in the abstract text. |
|
| • |
Approval of the animal research and ethics committee |
| |
--- Select whether you have obtained an approval of the committee, e.g. IACUC, or not applicable. The author is not required to mention it in the abstract text. |
|
| • |
Duplicate submission (presentation) |
| |
--- Select whether a duplicate submission is suspected or not applicable. This does not need to be stated in the abstract text. |
|
| • |
Conflict of Interest (COI) |
| |
--- Select whether you have any COI to be disclosed for the author (including co-authors) or not, according to “the detailed rules of the standard for disclosure in the Japanese Ophthalmological Society. " For categories F, C and R, only class IV (over 5,000,000 yen) will be correspond to “presence" (should be disclosed). |
|
|
| |
|
(2) |
Refer the following guidelines and submit your abstract via e-mail to Abstract Submission office (ringan2021-abs@congre.co.jp). |
|
| |
|
| |
|
|
Guidelines for Abstract Preparation |
|
|
|
|
| |
| 1. |
Papers that have been or will be presented in other academic meetings in Japan or that have already been published in Japan cannot be accepted. |
|
| 2. |
A presenter may make only one general presentation, as the first author. |
|
| 3. |
Abstract title, abstract title (shortened), first author & co-authors (if any) and their affiliations, abstract body must be included in your abstract file. |
|
| 4. |
| Abstract text: |
|
| |
The abstract title is limited to 80 characters |
|
| |
The abstract title (shortened) is limited to 30 characters |
|
| |
The abstract text is limited to 1200 characters |
|
| The title should be no longer than 80 characters including spaces, affiliation should be concise and the abstract no longer than 1200 characters including spaces. The shortened title should be no longer than 30 characters including spaces. |
|
|
| 5. |
The abstract should be structured with the following headings: - Objective, Subjects and Methods, Results, and Conclusions, in that order. For case reports and invention or improvement of techniques and devices, the headings should be appropriately changed (for example, for case reports, Introduction, Cases, Discussion and, if relevant, Conclusions). |
|
| 6. |
Methods, Results, etc. should be described clearly, with numerical values and the statistical analysis methods used, where possible. Invention or improvement of techniques and devices should also be described clearly. |
|
| 7. |
The Conclusion and Discussion should correspond to the Results described. |
|
| 8. |
Common names should be used for chemicals. Trade names should be given (……®) after the common names, if necessary (Example: timolol maleate [Timoptol®]). |
|
| 9. |
Presentations, abstracts and presentation data must be prepared in English. |
|
| 10. |
Declaration of conflict of interests is mandatory for author (presenter) and co-authors (co-presenters) (See below for details). |
|
|
|
|
| |
| 1. |
When a duplicate submission (presentation) is suspected, please contact the Committee for Judging Duplicate Presentations of the Japanese Ophthalmological Society in advance. |
|
| 2. |
When a duplicate submission (presentation) is confirmed after the registration deadline, presentations by the author (presenter) and co-authors (co-presenters) of the abstract may be temporarily suspended. In addition, their names may also be published in the Japanese Journal of Ophthalmology. |
|
| 3. |
The content of the abstract and its description are equally evaluated by peer review, and revisions are not allowed after the registration deadline. |
|
| 4. |
When the presentation includes part of the research conducted by multiple institutions, agreement of the persons concerned should be obtained, and the content of the agreement should be described in the Abstract. |
|
| 5. |
Meaningless rhetoric, prefixes (for example, Mr., Ms., Prof. and Dr.) inappropriate for academic papers, should not be used. |
|
| 6. |
Abstracts without data in the Results section, such as those that only state “will be investigated" and “we describe…," may be rejected. |
|
| 7. |
Conclusions should not be drawn from any content(s) not described in the Results. |
|
| 8. |
Withdrawal and revision after the registration deadline are not allowed under any circumstances. |
|
| * |
Please note that if a presenter does not make a presentation at the designated time and place without prior notice, as a penalty the presenter will not be allowed to make a presentation as the first presenter in the next meeting. This policy was laid down by the Program Committee of the Japanese Ophthalmological Society. If unable to attend the meeting for any compelling reason on the designated day and time, the presenter must inform the conference secretariat promptly and submit a statement of reasons for absence to the conference secretariat by e-mail by the end of the meeting. |
|
|
|
|
|
| |
| When making a presentation at the Annual Meeting of the Japanese Ophthalmological Society and the Annual Congress of Japan Clinical Ophthalmology, the authors have to report any conflict of interest based on “the rules for conflict of interest of Japanese Ophthalmological Society." If the presentation is accepted, the category of conflict of interest and company names must be disclosed in the slide and poster for presentation, based on “the rules for conflict of interest of Japanese Ophthalmological Society." |
|
A. |
Presentations to Which These Rules are Applicable |
|
| |
These rules are applicable to all presentations, including those in Co-Sponsored Seminars, Special Lectures, Invited Lectures, Symposia, Instruction Courses, General Presentations (including posters), etc., |
|
B. |
Report on Conflict of Interest at Abstract Submission |
|
| |
Report the potential conflict of interest with companies within the last three years no matter whether it's concerned with or without the content of your presentation. If conflict of interest is “present," enter the category, class and company names after each author's name in the entry field of “Conflict of Interest" on the entry form. Confirm the declaration is correct prior to the registration. Categories and classes are as follows. |
|
1.Category |
|
| |
F (Financial Support): |
| |
In the case where research expenses are supported or free research materials (including devices) or services (including sample measurements) are provided by companies (*) through the organization to which the author belongs.
(*) Companies denote both related companies and competitor companies. This is also the case for all subsequent categories. |
|
| |
I (Personal Financial Interest): |
| |
In the case where the author is an investor in a company related to the chemicals and materials (including devices) used and services are provided. |
|
| |
E (Employee): |
| |
In the case where the author is an employee of an interested company. |
|
| |
C (Consultant): |
| |
In the case where the author is currently, or was within the past three years, a consultant of an interested company. |
|
| |
P (Patent): |
| |
In the case where the author holds a patent or is in the process of applying for a patent. |
|
| |
R: |
| |
In the case where the author receives rewards (*) or travel expenses from a company related to the chemicals and materials (including devices) used and services provided. |
|
| |
(*) Rewards include salaries, travel fees, intellectual property rights, royalties, honoraria, shares, stock options, consultancy fees, lecture fees, expenses as a member of advisory committees and review panels, etc. |
|
2.Class |
|
| |
| Ⅰ. |
0 yen |
|
| Ⅱ. |
From 1 to less than 500,000 yen |
|
| Ⅲ. |
From 500,000 to 5,000,000 yen |
|
| Ⅳ. |
Over 5,000,000 yen |
|
| * |
Conflict of interest should be disclosed for the fiscal year during the previous three years when the author received the largest sum of money. |
|
|
C. |
Disclosure in the Abstract and Slide |
|
| |
Abstract: |
| |
The presence or absence of conflict of interest to be disclosed for the author (including co-authors) should be stated in the entry form. |
|
| |
Presentation Data: |
| |
If the authors have to disclose any conflict of interest, the category and company names* should be described after the authors' names in the second slide. For categories F, C and R, only class IV (over 5,000,000 yen) should be disclosed. |
|
| |
| * |
In the case of "Category P" (the author holds a patent or is in the process of applying for a patent), the company name need not to described.
If all authors do not have any conflict of interest to disclose, there will be a statement to the effect, “there is no conflict of interest to be disclosed".
Thank you for your cooperation. Please contact the conference secretariat for any questions by e-mail. |
|
|
| |
Sample slides will be provided from the Abstract Submission office. |
|
|
|
| |
|
|
Personal Information Protection |
|
|
|
|
| |
| "Names" and "contact addresses" provided to us at registration for the meeting shall be used for the purpose of contact from the secretariat, notification of acceptance or rejection, and any information related to the presentation. In addition, the “presenters' names," “affiliation names," “title" and “abstract text" shall be used for publication in the program/proceedings and on the website, but not for other purposes. The registration process for applications has been commissioned to c/o Congress Corporation in order to facilitate management operations. |
|
|
|
|
| |
| Congress Secretariat of the 75th Annual Congress of Japan Clinical Ophthalmology is committed to protecting and respecting your personal information and privacy. Any information provided for registration will not be used for purposes other than administering the 75th Annual Congress of Japan Clinical Ophthalmology. |
|
|
|
| |
|
|
Notification of Abstracts |
|
|
|
|
| |
| Notification of acceptance or rejection will be sent to the registered e-mail address around July, 2021 (tentative). |
|
|
|
|
| |
The 75th Annual Congress of Japan Clinical Ophthalmology Secretariat
Abstract Submission office
c/o Congrès Inc.
Tel: +81-92-716-7116 Fax: +81-92-716-7143
E-mail: ringan2021-abs@congre.co.jp |
|
|
|
|
|
|
|
| Copyright © The 75th Annual Congress of Japan Clinical Ophthalmology. All Rights Reserved. |
|
